Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.56 |
| ▸ | LDHA | P00338 | 2/20 | 0.53 |
| ▸ | LDHB | P07195 | 1/20 | 0.53 |
| ▸ | HAO1 | Q9UJM8 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.52 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.51 |
| ▸ | PPARA | Q07869 | 1/20 | 0.51 |
| ▸ | STING1 | Q86WV6 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.48 |
| ▸ | MEN1 | O00255 | 4/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.48 |
| ▸ | NPC1 | O15118 | 2/20 | 0.48 |
| ▸ | PKM | P14618 | 1/20 | 0.48 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29390925 | 1.00 | MAPT (0.56) | MAPTLDHALDHBHAO1ALDH1A1 | |
| SCHEMBL29388237 | 0.93 | ALDH1A1 (0.58) | MAPTLDHALDHBHAO1ALDH1A1 | |
| SCHEMBL609849 | 0.93 | ALDH1A1 (0.58) | MAPTLDHALDHBHAO1ALDH1A1 | |
| SCHEMBL611465 | 0.87 | KDM4C (0.67) | MAPTLDHALDHBHAO1ALDH1A1 | |
| SCHEMBL29388556 | 0.87 | KDM4C (0.67) | MAPTLDHALDHBHAO1ALDH1A1 | |
| SCHEMBL12086223 | 0.83 | LCK (0.64) | MAPTLDHALDHBHAO1ALDH1A1 | |
| SCHEMBL608754 | 0.83 | NOX4 (0.61) | MAPTALDH1A1TDP1KDM4CPPARA | |
| SCHEMBL610123 | 0.82 | SYK (0.58) | MAPTALDH1A1TDP1KDM4CPPARA | |
| SCHEMBL4095004 | 0.82 | KDM4C (0.56) | MAPTALDH1A1TDP1KDM4CPPARA | |
| SCHEMBL29388077 | 0.82 | SYK (0.58) | MAPTALDH1A1TDP1KDM4CPPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 70 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3902536-B1 | COMPOSITIONS COMPRISING 5-BENZYLAMINOSALICYLIC ACID COMPOUNDS FOR USE IN TREATING NEURODEGENERATIVE DISORDERS IN A COMPANION ANIMAL | GNT PHARMA CO LTD (KR) | 2025-09-03 | — | — | EP | claimed |
| WO-2023156808-A2 | COMPOSITIONS AND METHODS FOR TREATING PULMONARY DISORDERS | GNT PHARMA CO., LTD. (KR) | 2023-08-24 | — | — | WO | claimed |
| US-20230233503-A1 | COMPOSITIONS AND METHODS FOR TREATING PULMONARY DISORDERS | GNT PHARMA CO., LTD. (KR) | 2023-07-27 | — | — | US | claimed |
| US-20220249343-A1 | COSMETIC COMPOSITION INCLUDING 5-BENZYLAMINOSALICYLIC ACID DERIVATIVE, AND TOPICAL USE THEREOF | GNT PHARMA CO., LTD. (KR) | 2022-08-11 | — | — | US | claimed |
| US-20220241231-A1 | COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISORDERS | GNT PHARMA CO., LTD. (KR) | 2022-08-04 | — | — | US | claimed |
| EP-3998058-A1 | COSMETIC COMPOSITION COMPRISING 5-BENZYLAMINOSALICYLIC ACID DERIVATIVE AND LOCAL ADMINISTRATION METHOD THEREOF | GNT Pharma Co., Ltd (KR) | 2022-05-18 | — | — | EP | claimed |
| CN-114096227-A | Cosmetic compositions comprising 5-benzylaminosalicylic acid derivatives and methods of topical use thereof | 吉恩特药业株式会社 | 2022-02-25 | — | — | CN | claimed |
| CN-113710242-A | Compositions and methods for treating neurodegenerative disorders | 吉恩特药业株式会社 | 2021-11-26 | — | — | CN | claimed |
| EP-3902536-A1 | COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISORDERS | GNT Pharma Co., Ltd (KR) | 2021-11-03 | — | — | EP | claimed |
| WO-2020136441-A1 | COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISORDERS | GNT PHARMA CO., LTD. (KR) | 2020-07-02 | — | — | WO | claimed |
| US-20200206172-A1 | COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISORDERS | GNT PHARMA CO., LTD. (KR) | 2020-07-02 | — | — | US | claimed |
| US-20120301551-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING NEURONAL DEATH OR NEUROLOGICAL DYSFUNCTION | NEUROTECH PHARMACEUTICALS CO., LTD. (KR) | 2012-11-29 | — | — | US | claimed |
| US-20120040939-A1 | MEDICINAL USE OF 5-BENZYLAMINOSALICYLIC ACID DERIVATIVE OR ITS SALT | NEUROTECH PHARMACEUTICALS CO., LTD. (KR) | 2012-02-16 | — | — | US | claimed |
| US-20070298129-A1 | Compounds and compositions for treating neuronal death or neurological dysfunction | NEUROTECH PHARMACEUTICALS CO., LTD. (KR) | 2007-12-27 | — | — | US | claimed |
| US-20070049565-A1 | Combination of cell necrosis inhibitor and lithium for treating neuronal death or neurological dysfunction | NEUROTECH PHARMACEUTICALS CO., LTD. (KR) | 2007-03-01 | — | — | US | claimed |
| US-6964982-B2 | Compounds, compositions and methods for preventing neurodegeneration in acute and chronic injuries in the central nervous system | NEUROTECH CO., LTD. (KR) | 2005-11-15 | — | — | US | claimed |
| EP-1274675-B1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR PREVENTING NEURODEGENERATION IN ACUTE AND CHRONIC INJURIES IN THE CENTRAL NERVOUS SYSTEM | NEUROTECH CO LTD (KR) | 2004-09-01 | — | — | EP | claimed |
| US-20030045575-A1 | Compounds, compositions and methods for preventing neurodegeneration in acute and chronic injuries in the central nervous system | NEUROTECH CO., LTD. | 2003-03-06 | — | — | US | claimed |
| EP-3902536-B1 | COMPOSITIONS COMPRISING 5-BENZYLAMINOSALICYLIC ACID COMPOUNDS FOR USE IN TREATING NEURODEGENERATIVE DISORDERS IN A COMPANION ANIMAL | GNT PHARMA CO LTD (KR) | 2025-09-03 | — | — | EP | disclosed |
| WO-2001079153-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR PREVENTING NEURODEGENERATION IN ACUTE AND CHRONIC INJURIES IN THE CENTRAL NERVOUS SYSTEM | NEUROTECH CO., LTD. (KR) | 2001-10-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120301551-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING NEURONAL DEATH OR NEUROLOGICAL DYSFUNCTION | BCL2, BAX, SMN1; SMN2 | MAPT 28/4885LDHA 55/4885LDHB 40/4885 |
| US-20230233503-A1 | COMPOSITIONS AND METHODS FOR TREATING PULMONARY DISORDERS | HAO2, ACOX1, HAO1 | MAPT 3976/4885LDHA 1013/4885LDHB 324/4885 |
| US-20220241231-A1 | COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISORDERS | PRNP, PSEN1, GRIK5 | MAPT 19/4885LDHA 1037/4885LDHB 1752/4885 |
| US-20070298129-A1 | Compounds and compositions for treating neuronal death or neurological dysfunction | BCL2, BAX, SMN1; SMN2 | MAPT 28/4885LDHA 55/4885LDHB 40/4885 |
| US-20120040939-A1 | MEDICINAL USE OF 5-BENZYLAMINOSALICYLIC ACID DERIVATIVE OR ITS SALT | HTR5A, HTR6, MC5R | MAPT 2420/4885LDHA 879/4885LDHB 1127/4885 |
| US-20070049565-A1 | Combination of cell necrosis inhibitor and lithium for treating neuronal death or neurological dysfunction | BAD, MAP1LC3B, XIAP | MAPT 33/4885LDHA 41/4885LDHB 24/4885 |
| US-20220249343-A1 | COSMETIC COMPOSITION INCLUDING 5-BENZYLAMINOSALICYLIC ACID DERIVATIVE, AND TOPICAL USE THEREOF | ALOX5, ALOX15, IL5 | MAPT 3381/4885LDHA 2849/4885LDHB 3015/4885 |
| US-20030045575-A1 | Compounds, compositions and methods for preventing neurodegeneration in acute and chronic injuries in the central nervous system | GRIK5, GRIN2A, GRIN2C | MAPT 184/4885LDHA 1947/4885LDHB 2310/4885 |
| US-20200206172-A1 | COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISORDERS | PRNP, PSEN1, GRIK5 | MAPT 19/4885LDHA 1037/4885LDHB 1752/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.